Facebook
Twitter
LinkedIn
Forward2024 Spring Symposium Recorded Session: The In vitro and In vivo Development of a GLP-1 Stimulating Nutraceutical: Taking a Full Pharmacological Approach
Bitter hops extract is a novel gut-targeted plant-based nutraceutical for appetite control and long-term weight management, which was developed as part of a $20 million government research project and has received an additional $10 million in government and investor funding. A comprehensive research methodology comprised of hospital-based gut biopsy studies, robot-assisted high throughput screening, and clinical validation was undertaken, exemplifying how nutraceutical development should be conducted, and ultimately leading to the development of this highly bioactive ingredient that shares an overlapping mode of action with a new class of effective GLP-1-based anti-obesity drugs.
Join Edward Walker, PhD, for a presentation explores the scientific and clinical approach used to demonstrate the efficacy of bitter hops extract as a nutraceutical, with a stringent pharmacological approach, ensuring the clinical efficacy of this ingredient.
Learning Objectives
After completing this activity, nutrition professionals will better be able to:
- Discuss the effect of bitter plant compounds on appetite.
- Describe the human gut’s bitter taste receptors.
- Evaluate clinical studies demonstrating the activation of bitter brake in the lab.
Additional Information
Edward Walker, PhD, is a scientist and lecturer, who believes that developing a healthy relationship with food is key for long-term wellness. He works at Plant & Food Research, undertaking commercially focused research of nutraceutical products for human health applications, with a focus on clinical validation of lab-based results. He is also a guest lecturer at the University of Auckland on the topic of nutraceuticals and functional foods.
Over the last 13 years Dr. Walker’s primary research focus has been the investigation of plant-based appetite suppressants that may reduce hunger and support healthy food choices. He is passionate about plant-based nutraceuticals and believes that with the appropriate scientific research, they have the potential to improve health and even prevent or delay the development of chronic disease.
Disclosures: Edward Walker, PhD, has the following relevant relationships to disclose: he has received research grant support from Calocurb.
Funding from non-CPE revenue for CPE planning, development, review, and/or presentation has been provided by Calocurb.
The In vitro and In vivo Development of a GLP-1 Stimulating Nutraceutical: Taking a Full Pharmacological Approach awards 1.25 CPEUs in accordance with the Commission on Dietetic Registration’s CPEU Prior Approval Program.
The responsible provider for this activity is Calocurb.
Funding from non-CPE revenue for CPE planning, development, review, and/or presentation has been provided by Calocurb.
Available Credit
- 1.25 CDR
Price
Required Hardware/software
Ensure your browser's cookies are enabled in order for the video software to function properly.